Reaction of the bone structure to methotrexate-Palacos flow y. Experimental investigations in animals.
With the combined osteosynthesis of pathological fractures in association with tumors and/or metastases in mind, E. Merck (Darmstadt, FRG) developed a bone cement containing a cytostatic agent, methotrexate-Palacos flow y (MTX-Pf). The animal-experimental study presented here investigates the tolerability of MTX-Pf in the femurs of rabbits with lateral comparison. In these investigations we used both the concentration of 0.63% MTX, as is currently used in standard clinical surgery, as well as a much higher concentration of 2.5% MTX. The histological sections were investigated using microradiographic methods and provided no indication of any significant differences between the femora with the MTX-Pf implantation and those into which standard Palacos flow y had been implanted.
Degreif
J
J
Clinic and Polyclinic for Accident Surgery, Johannes Gutenberg University, Mainz, Federal Republic of Germany.
Rudigier
J
J
Rudig
L
L
Wahlig
H
H
Dingeldein
E
E
D000818:Animals; D001843:Bone Cements / Q000494:pharmacology / Q000627:therapeutic use*; D001842:Bone and Bones / Q000187:drug effects* / Q000473:pathology; D005594:Fracture Fixation, Intramedullary; D050723:Fractures, Bone / Q000601:surgery*; D008727:Methotrexate / Q000494:pharmacology / Q000627:therapeutic use*; D011817:Rabbits; D014945:Wound Healing
D001843:Bone Cements; D008727:Methotrexate